Hikma Prescribed drugs PLC (OTCPK:HKMPY) Shareholder/Analyst Name November 6, 2025 4:30 AM EST
Firm Contributors
Riad Mishlawi – Interim Head of Injectables Enterprise, CEO & Director
Khalid Nabilsi – Chief Monetary Officer
Convention Name Contributors
Zain Ebrahim – JPMorgan Chase & Co, Analysis Division
Charlie Haywood – BofA Securities, Analysis Division
Christian Glennie – Stifel, Nicolaus & Firm, Integrated, Analysis Division
Victor Floch – BNP Paribas, Analysis Division
Beatrice Fairbairn – Joh. Berenberg, Gossler & Co. KG, Analysis Division
Kane Slutzkin – Deutsche Financial institution AG, Analysis Division
James Vane-Tempest – Jefferies LLC, Analysis Division
Sebastien Jantet – Panmure Liberum Restricted, Analysis Division
Miles Dixon – Peel Hunt LLP, Analysis Division
Presentation
Operator
Good day, girls and gents, and welcome to Hikma November 2025 Buying and selling Replace.
[Operator Instructions]
I’ll now hand over to Investor Relations for opening remarks. Please go forward.
Unknown Govt
Thanks. Earlier than we begin, we would prefer to remind you that any forward-looking statements or projections made by Hikma throughout this name are made in good religion primarily based on info at present accessible and topic to dangers and uncertainties which will trigger precise outcomes to vary materially from these projected. For additional info, please see the Principal Dangers and Uncertainties part in Hikmas’s newest annual report. And with that, let me hand over to our CEO, Riad Mishlawi.
Riad Mishlawi
Interim Head of Injectables Enterprise, CEO & Director
Many thanks. Good morning, everybody, and thanks for all becoming a member of this name relating to our November buying and selling replace that we now have revealed this morning. Earlier than we come to your questions, I need to briefly cowl a handful of key factors within the replace. Firstly, the enterprise is performing effectively, and we’re on monitor to fulfill our 2025 steering. It’s actually encouraging to see all 3 companies doing effectively. Secondly, we all know that there’s a key concentrate on the injectable margins. We now have at all times achieved industry-leading margins